CoChat
Sign Up
Cited by 198Obstructive Sleep Apnea ResearchNeuroscience of respiration and sleepSleep and related disorders

Obesity, obstructive sleep apnoea and metabolic syndrome

Open access
LAM, JAMIE CHUNG MEI, MAK, JUDITH CHOI WO, IP, MARY SAU MAN·2012·Respirology
DOI 10.1111/j.1440-1843.2011.02081.x
Open this paper in CoChat — free accountOpen PDF

Abstract

OSA is increasingly recognized as a major health problem in developed countries. Obesity is the most common risk factor in OSA and hence, the prevalence of OSA is undoubtedly rising given the epidemic of obesity. Recent data also suggest that OSA is highly associated with the metabolic syndrome, and it is postulated that OSA contributes to cardiometabolic dysfunction, and subsequently vasculopathy. Current evidence regarding the magnitude of impact on ultimate cardiovascular morbidity or mortality attributable to OSA‐induced metabolic dysregulation is scarce. Given the known pathophysiological triggers of intermittent hypoxia and sleep fragmentation in OSA, the potential mechanisms of OSA–obesity–metabolic syndrome interaction involve sympathetic activation, oxidative stress, inflammation and neurohumoral changes. There is accumulating evidence from human and animal/cell models of intermittent hypoxia to map out these mechanistic pathways. In spite of support for an independent role of OSA in the contribution towards metabolic dysfunction, a healthy diet and appropriate lifestyle modifications towards better control of metabolic function are equally important as CPAP treatment in the holistic management of OSA.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1440-1843.2011.02081.x

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 138

  1. CDC. State-specific prevalence of obesity among adults- United States. MMWR Morb. Mortal. Wkly. Rep. 2005; 55: 985- 8.
  2. Poirier P, Giles TD, Bray GA et al. Obesity and cardiovascular disease-Pathophysiology, evaluation, and effect of weight loss. Arterioscler. Thromb. Vasc. Biol. 2006; 26: 968-76.
  3. Prospective Studies Collaboration. Body mass index and cause specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373: 1083-96.
  4. Coughlin S, Mawdsley L, Mugarza JA et al. Obstructive sleep apnoea is independently associated with an increased preva- lence of metabolic syndrome. Eur. Heart J. 2004; 25: 735-41.
  5. Lam JCM, Lam B, Lam CL et al. Obstructive sleep apnea and the metabolic syndrome in community-based Chinese subjects in Hong Kong. Respir. Med. 2006; 100: 980-87.
  6. Young T, Shahar E, Nieto F et al. Predictors of sleep-disordered breathing in community dwelling adults: the Sleep Heart Health Study. Arch. Intern. Med. 2002; 162: 893-900.
  7. Pack AI, Pien GW. Update on sleep and its disorders. Annu. Rev. Med. 2011; 62: 447-60.
  8. Williams G, Fruhbeck G (eds). Obesity: Science and Practice. Wiley, Oxford, 2009. 10 Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Resp Ser 2000; 894: i-xii, 1-253.
  9. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and interven- tion strategies. Lancet 2004; 363: 157-63.
  10. Grassi G, Seravalle G, Del'Orro R. Sympathetic activation in obesity: a noninnocent bystander. Hypertension 2010; 56: 338- 40.
  11. Reaven G. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
  12. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syn- drome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-16.
  13. Hanson RL, Imperatore G, Bennett PH et al. Components of the 'metabolic syndrome' and incidence of type 2 diabetes. Diabe- tes 2002; 51: 3120-27.
  14. Simons LA, Simons J, Friedlander Y et al. Is prediction of cardio- vascular disease and all-cause mortality genuinely driven by the metabolic syndrome, and independently from its component variables? The Dubbo study. Heart Lung Circ. 2011; 20: 214-19.
  15. Eckel RH, Grundy SM. The metabolic syndrome. Lancet 2005; 365: 1415-28.
  16. Lam JC, Ip MS. Sleep and the metabolic syndrome. Indian J. Med. Res. 2010; 131: 206-16.
  17. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol. Metab. Clin. North Am. 2004; 33: 351-75.
  18. Weiss R, Dziura J, Burgert TS et al. Obesity and the metabolic syndrome in children and adolescent. N. Engl. J. Med. 2004; 350: 2362-74.
  19. Grundy SM, Cleeman JI, Daniels RD et al. Diagnosis and management of the metabolic syndrome-an American Heart Association/National Heart, Lung, and Blood Institute Scien- tific Statement. Circulation 2005; 112: 2735-52.
  20. Jensen MD. Is visceral fat involved in the pathogenesis of the metabolic syndrome? Human model. Obesity 2006; 14: S20-24.
  21. Kissebath AH. Central obesity: measurement and metabolic effects. Diabet. Rev. 1997; 5: 8-20.
  22. Newman AB, Foster G, Givelber R et al. Progression and regres- sion of sleep-disordered breathing with changes in weight: the Sleep Heart Health Study. Arch. Intern. Med. 2005; 165: 2408-13.
  23. Phillips BG, Kato M, Narkiewicz K et al. Increases in leptin levels, sympathetic drive, and weight gain in obstructive sleep apnea. Am. J. Physiol. Heart Circ. Physiol. 2000; 279: H234-7.
  24. Onat A, Hergenc G, Yuksel H et al. Neck circumference as a measure of central obesity: associations with metabolic syn- drome and obstructive sleep apnea beyond waist circumfer- ence. Clin. Nutr. 2009; 28: 46-51.
  25. Sharma SK, Kurian S, Malik V et al. A stepped approach for prediction of obstructive sleep apnea in overtly asymptomatic obese subjects: a hospital based study. Sleep Med. 2004; 5: 351-7.
  26. Kawaguchi Y, Fukumoto S, Inaba M et al. Different impacts of neck circumference and visceral obesity on the severity of obstructive sleep apnea syndrome. Obesity 2011; 19: 276-82.
  27. McClendon DA, Dunbar SB, Clark PC et al. An analysis of popular weight loss diet types in relation to metabolic syn- drome therapeutic guidelines. Review. Medsurg Nurs. 2010; 19: 17-24.
  28. Haines KL, Nelson LG, Gonzalez R et al. Objective evidence that bariatric surgery improves obesity-related obstructive sleep apnea. Surgery 2007; 141: 354-8.
  29. Sutherland K, Lee RW, Phillips CL et al. Effect of weight loss on upper airway size and facial fat in men with obstructive sleep apnoea. Thorax 2011; 66: 797-803.
  30. Grunstein RR, Stenlof K, Hedner JA et al. Two year reduction in sleep apnea syndromes and associated diabetes incidence after weight loss in severe obesity. Sleep 2007; 30: 703-10.
  31. Phillips CL, Yee BJ, Trenell MI et al. Changes in regional adipos- ity and cardiometabolic function following a weight loss program with Sibutramine in obese men with obstructive sleep apnea. J. Clin. Sleep Med. 2009; 5: 416-21.
  32. Dixon JB, Schachter LM, O'Brien PE. Polysomnography before and after weight loss in obese patients with severe sleep apnea. Int. J. Obes. (Lond) 2005; 29: 1048-54.
  33. Vgontzas AN. Does obesity play a major role in the pathogen- esis of sleep apnoea and its associated manifestations via inflammation, visceral adiposity, and insulin resistance? Arch. Physiol. Biochem. 2008; 114: 211-23.
  34. Rosmond R, Dallman MF, Bjorntorp P. Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J. Clin. Endocrinol. Metab. 1998; 83: 1853-9.
  35. Grunstein RR, Wilcox I, Yang TS et al. Snoring and sleep apnea in men: association with central obesity and hypertension. Int. J. Obes. Relat. Metab. Disord. 1993; 17: 533-40.
  36. Tasali E, Van Cauter E. Sleep disordered breathing and the current epidemic of obesity-consequence or contributing factor? The editorials. Am. J. Respir. Crit. Care Med. 2002; 165: 562-3.
  37. Vgontzas AN, Bixler EO, Chrousos GP. Sleep apnea is a mani- festation of the metabolic syndrome. Sleep Med. Rev. 2005; 9: 211-24.
  38. Trayhurn P, Wang B, Wood IS. Hypoxia in adipose tissue: a basis for the dysregulation of tissue function in obesity? Br. J. Nutr. 2008; 100: 227-35.
  39. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2004; 444: 860-7.
  40. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardio- vascular disease. Circ. Res. 2005; 96: 939-49.
  41. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of non-alcoholic steatohepatitis and liver fibrosis in severely obese. Gastroenterology 2001; 121: 91-100.
  42. Browning JD, Horton JD. Molecular mediators of hepatic ste- atosis and liver injury. J. Clin. Invest. 2004; 114: 147-52.
  43. Norman D, Bardwell WA, Arosemena F et al. Serum aminotrans- ferase levels are associated with markers of hypoxia in patients with obstructive sleep apnea. Sleep 2008; 31: 121-6.
  44. Gruber A, Horwood F, Sithole J et al. Obstructive sleep apnoea is independently associated with metabolic syndrome but not the insulin resistance state. Cardiovasc. Diabetol. 2006; 5: 22(1- 7).
  45. Parish JM, Adam T, Facchiano L. Relationship of metabolic syn- drome and obstructive sleep apnea. J. Clin. Sleep Med. 2007; 3: 467-72.
  46. Nieto FJ, Peppard PF, Young TB. Sleep disordered breathing and metabolic syndrome. WMJ 2009; 108: 263-5.
  47. Oktay B, Akbal E, Firat H et al. CPAP treatment in the coexist- ence of obstructive sleep apnea syndrome and metabolic syn- drome, results of one year follow up. Acta Clin. Belg. 2009; 64: 329-34.
  48. Drager LF, Queiroz EL, Lopes HF et al. Obstructive sleep apnea is highly prevalent and correlates with impaired glycemic control in consecutive patients with the metabolic syndrome. J. Cardiometab. Syndr. 2009; 4: 89-95.
  49. Trombetta IC, Somers VK, Maki-Nunes C et al. Consequences of comorbid sleep apnea in the metabolic syndrome- implications for cardiovascular risk. Sleep 2010; 33: 1193-9.
  50. Ambrosetti M, Lucioni AM, Conti S et al. Metabolic syndrome in obstructive sleep apnea and related cardiovascular risk. J. Cardiovasc. Med. 2006; 7: 826-9.
  51. Peled N, Kassirer M, Shitrit D et al. The association of OSA with insulin resistance, inflammation and metabolic syndrome. Respir. Med. 2007; 101: 1696-701.
  52. Papanas N, Steiropoulos P, Nena E et al. Predictors of obstruc- tive sleep apnea in males with metabolic syndrome. Vasc. Health Risk Manag. 2010; 6: 281-6.
  53. Barcelo A, Pierola J, de la Pena M et al. Free fatty acids and the metabolic syndrome in patients with obstructive sleep apnoea. Eur. Respir. J. 2011; 37: 1418-23.
  54. Zito A, Steiropoulos P, Barcelo A et al. Obstructive sleep apnoea and metabolic syndrome in Mediterranean countries. Eur. Respir. J. 2011; 37: 717-19.
  55. Gasa M, Salord N, Fortuna AM et al. Obstructive sleep apnoea and metabolic impairment in severe obesity. Eur. Respir. J. 2011; 38: 1089-97.
  56. Sasanabe R, Banno K, Otake K et al. Metabolic syndrome in Japanese patients with obstructive sleep apnea syndrome. Hypertens. Res. 2006; 29: 315-22.
  57. Shiina K, Tomiyama H, Takata Y et al. Concurrent presence of metabolic syndrome in obstructive sleep apnea syndrome exacerbates the cardiovascular risk. A sleep clinic cohort study. Hypertens. Res. 2006; 29: 433-41.
  58. Akahoshi T, Uematsu A, Akashiba T et al. Obstructive sleep apnoea is associated with risk factors comprising the metabolic syndrome. Respirology 2010; 15: 1122-6.
  59. Takama N, Kurabayashi M. Relationship between metabolic syndrome and sleep-disordered breathing in patients with car- diovascular disease-metabolic syndrome as a strong factor of nocturnal desaturation. Intern Med 2008; 47: 709-15.
  60. Kono M, Tatsumi K, Saibara T et al. Obstructive sleep apnea syndrome is associated with some components of metabolic syndrome. Chest 2007; 131: 1387-92.
  61. McArdle N, Hillman D, Beilin L et al. Metabolic risk factors for vascular disease in obstructive sleep apnea: a matched con- trolled study. Am. J. Respir. Crit. Care Med. 2007; 175: 190-95.
  62. Sharma SK, Sreenivas V. Are metabolic syndrome, obstructive sleep apnea, syndrome Z sequential?-a hypothesis. Indian J. Med. Res. 2010; 131: 455-8.
  63. Drager LF, Bortolotto LA, Maki-Nunes C et al. The incremental role of obstructive sleep apnea on markers of atherosclerosis in patients with metabolic syndrome. Artherosclerosis 2010; 208: 490-95.
  64. Mota PC, Drummond M, Winck JC et al. APAP impact on meta- bolic syndrome in obstructive sleep apnea patients. Sleep Breath. 2010; doi: 10.1007/S11325-010-0417-5. · DOI
  65. Lavie L, Polotsky V. Cardiovascular aspects in obstructive sleep apnea syndrome-molecular issues, hypoxia and cytokine pro- files. Respiration 2009; 78: 361-70.
  66. Dyugovskaya L, Lavie P, Lavie L. Increased adhesion molecules expression and production of reactive oxygen species in leuko- cytes of sleep apnea patients. Am. J. Respir. Crit. Care Med. 2002; 165: 934-9.
  67. Barcelo A, Miralles C, Barbe F et al. Abnormal lipid peroxi- dation in patients with sleep apnoea. Eur. Respir. J. 2000; 16: 644-7.
  68. Yamauchi M, Nakano H, Maekawa J et al. Oxidative stress in obstructive sleep apnea. Chest 2005; 127: 1674-9.
  69. Carpagnano GE, Kharitonov SA, Resta O et al. 8-isoprostane, a marker of oxidative stress, is increased in exhaled breath con- densate of patients with obstructive sleep apnea after night and is reduced by continuous positive airway pressure therapy. Chest 2003; 124: 1386-92.
  70. Pialoux V, Hanly PJ, Foster GE et al. Effects of exposure to inter- mittent hypoxia on oxidative stress and acute hypoxic ventilatory response in humans. Am. J. Respir. Crit. Care Med. 2009; 180: 1002-9.
  71. Yuan G, Nanduri J, Khan S et al. Induction of HIF-1a expression by intermittent hypoxia: involvement of NADPH oxidase, Ca2+ signaling, prolyl hydroxylases, and mTOR. J. Cell. Physiol. 2008; 217: 674-85.
  72. Lavie L. Oxidative stress-a unifying paradigm in obstructive sleep apnea and comorbidities. Prog. Cardiovasc. Dis. 2009; 51: 303-12.
  73. Muraki I, Tanigawa T, Yamagishi K et al. Nocturnal intermittent hypoxia and the development of type 2 diabetes: the Circula- tory Risk in Communities Study (CIRCS). Diabetologia 2010; 53: 481-8.
  74. Sulit L, Storfer-isser A, Kirchner HL et al. Differences in poly- somnography predictors for hypertension and impaired glucose tolerance. Sleep 2006; 29: 777-83.
  75. Reichmuth KJ, Austin D, Skatrud B et al. Association of sleep apnea and type II diabetes: a population-based study. Am. J. Respir. Crit. Care Med. 2005; 172: 1590-95.
  76. Polotsky VY, Li J, Punjabi NM et al. Intermittent hypoxia increases insulin resistance in genetically obese mice. J. Physiol. 2003; 552: 253-64.
  77. Iiyori N, Alonso LC, Li J et al. Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity. Am. J. Respir. Crit. Care Med. 2007; 175: 851-7.
  78. Yokoe T, Alonso LC, Romano LC et al. Intermittent hypoxia reverses the diurnal glucose rhythm and causes pan- creatic beta-cell replication in mice. J. Physiol. 2008; 586: 899- 911.
  79. Bertuglia S, Reiter RJ. Melatonin reduces microvascular damage and insulin resistance in hamsters due to chronic intermittent hypoxia. J. Pineal Res. 2009; 46: 307-13.
  80. Xu J, Long YS, Gozal D et al. Beta-cell death and proliferation after intermittent hypoxia: role of oxidative stress. Free Radic. Biol. Med. 2009; 46: 783-90.
  81. Rosa DP, Martinez D, Picada JN et al. Hepatic oxidative stress in an animal model of sleep apnea: effects of different duration of exposure. Comp. Hepatol. 2011; 10: 1.
  82. Li J, Savransky V, Nanayakkara A et al. Hyperlipidemia and lipid peroxidation are dependent on the severity of chronic intermit- tent hypoxia. J. Appl. Physiol. 2007; 102: 557-63. 100
  83. Li J, Nanayakkara A, Jun J et al. Effect of deficiency in SREBP cleavage-activating protein on lipid metabolism during intermittent hypoxia. Physiol. Genomics 2007; 31: 273- 80. 101
  84. Arnaud C, Beguin PC, Lantuejoul S et al. The inflammatory pre- atherosclerotic remodeling induced by intermittent hypoxia is attenuated by RANTES/CCL5 inhibition. Am. J. Respir. Crit. Care Med. 2011; 184: 724-31. 102
  85. Dematteis M, Julien C, Guillermet C et al. Intermittent hypoxia induces early functional cardiovascular remodeling in mice. Am. J. Respir. Crit. Care Med. 2008; 177: 227-35. 103
  86. Savransky V, Nanayakkara A, Li J et al. Chronic intermittent hypoxia induces atherosclerosis. Am. J. Respir. Crit. Care Med. 2007; 175: 11290-97. 104
  87. Leinum CJ, Dopp JM, Morgan BJ. Sleep disordered breathing and obesity: pathophysiology, complications and treatment. Nutr. Clin. Pract. 2009; 24: 675-87. 105
  88. Kent BD, Ryan S, McNicholas WT. Obstructive sleep apnea and inflammation: relationship to cardiovascular co-morbidity. Respir. Physiol. Neurobiol. 2011; 178: 475-81. 106
  89. Calvin AD, Albuquerque FN, Lopez-Jimenez F et al. Obstructive sleep apnea, inflammation, and the metabolic syndrome. Metab. Syndr. Relat. Disord. 2009; 7: 271-8. 107
  90. Trakada G, Chrousos G, Pejovic S et al. Sleep apnea and its asso- ciation with the stress system, inflammation, insulin resistance and visceral obesity. Sleep Med. Clin. 2007; 2: 251-61. 108
  91. Reinke C, Bevans-Fonti S, Drager LF et al. Effects of different acute hypoxic regimens on tissue oxygen profiles and metabolic outcomes. J. Appl. Physiol. 2011; 111: 881-90. 109
  92. Nacher M, Serrano-Mollar A, Farre R et al. Recurrent obstruc- tive apneas trigger early systemic inflammation in a rat model of sleep apnea. Respir. Physiol. Neurobiol. 2007; 155: 93-6. 110
  93. Tam CS, Wong M, Tam K et al. The effect of acute intermittent hypercapnic hypoxia treatment on IL-6, TNF-alpha, and CRP levels in piglets. Sleep 2007; 30: 723-7. 111
  94. Williams A, Scharf SM. Obstructive sleep apnea, cardiovascular disease, and inflammation-is NFkappaB the key? Sleep Breath. 2007; 11: 69-76. 112
  95. Htoo AK, Greenberg H, Tongia S et al. Activation of nuclear factor kappaB in obstructive sleep apnea: a pathway leading to systemic inflammation. Sleep Breath. 2006; 10: 43-50. 113
  96. Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005; 112: 2660-67. 114
  97. Greenberg H, Ye X, Wilson D et al. Chronic intermittent hypoxia activates nuclear factor-kappaB in cardiovascular tissues in vivo. Biochem. Biophys. Res. Commun. 2006; 343: 591-6. 115
  98. Toffoli S, Roegiers A, Feron O et al. Intermittent hypoxia is an angiogenic inducer for endothelial cells: role of HIF-1. Angio- genesis 2009; 12: 47-67. 116
  99. Libby P, Ridker P, Maseri A. Inflammation and atheroslcerosis. Circulation 2005; 105: 1135-43. 117
  100. Park K, Steffes M, Lee DH et al. Association of inflammation with worsening HOMA-insulin resistance. Diabetologia. 2009; 52: 2337-44. 118
  101. Shamsuzzaman AS, Winnicki M, Lanfranchi P et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Cir- culation 2002; 105: 2462-4. 119
  102. Taheri S, Austin D, Lin L et al. Correlates of serum C-reactive protein (CRP)-no association with sleep duration for sleep dis- oredered breathing. Sleep 2007; 30: 991-6. 120
  103. Lui MM, Lam JC, Mak HK et al. C-reactive protein is associated with obstructive sleep apnea independent of visceral obesity. Chest 2009; 135: 950-56. 121
  104. Ishida K, Kato M, Kato Y et al. Appropriate use of nasal continu- ous positive airway pressure decreases elevated C-reactive protein in patients with obstructive sleep apnea. Chest 2009; 136: 125-9. 122
  105. Kohler MM, Ayers L, Pepperell JCT et al. Effects of continuous positive airway pressure on systemic inflammation in patients with moderate to severe obstructive sleep apnoea: a random- ized controlled trial. Thorax 2008; 64: 67-73. 123
  106. Stefan N, Vozarova B, Funahashi T et al. Plasma adiponectin concentration is associated with skeletal muscle insulin recep- tor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002; 51: 1884-8. 124
  107. Wolf AM, Wolf D, Rumpold H et al. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1 RA in human leukocytes. Biochem. Biophys. Res. Commun. 2004; 323: 630- 35. 125
  108. Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adi- ponectin. Circulation 1999; 100: 2473-6. 126
  109. Kumada M, Kihara S, Sumitsuji S et al. Association of hypoadi- ponectinemia with coronary artery disease in men. Arteriocler. Thromb. Vasc. Biol. 2003; 23: 85-9. 127
  110. Pischon T, Girman CJ, Hotamisligil GS et al. Plasma adiponec- tin levels and risk of myocardial infarction in man. JAMA 2004; 291: 1730-37. 128
  111. Makino S, Handa H, Suzukawa K et al. Obstructive sleep apnoea syndrome, plasma adiponectin levels, and insulin resistance. Clin. Endocrinol. (Oxf.) 2006; 64: 12-19. 129
  112. Wolk R, Svatikova A, Nelson CA et al. Plasma levels of adiponec- tin, a novel adipocyte-derived hormone, in sleep apnea. Obes. Res. 2005; 13: 186-90. 130
  113. Lam JC, Xu A, Tam S et al. Hypoadiponectinemia is related to the sympathetic activity and severity of obstructive sleep apnea. Sleep 2008; 31: 1721-7. 131
  114. Fasshauer M, Klein J, Neumann S et al. Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett. 2001; 507: 142-6. 132
  115. Carneiro G, Togeiro SM, Ribeiro-Filho FF et al. Continuous positive airway pressure therapy improves hypoadiponectine- mia in severe obese men with obstructive sleep apnea without changes in insulin resistance. Metab. Syndr. Relat. Disord. 2009; 7: 537-42. 133
  116. de Lima AM, Franco CM, de Castro CMM et al. Effects of nasal continuous positive airway pressure treatment on oxidative stress and adiponectin levels in obese patients with obstructive sleep apnea. Respiration 2010; 79: 370-76. 134
  117. West SD, Nicoll DJ, Wallace TM et al. Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax 2007; 62: 969-74. 135
  118. Magalang UJ, Cruff JP, Rajappan R et al. Intermittent hypoxia suppresses adiponectin secretion by adipocytes. Exp. Clin. Endocrinol. Diabetes 2009; 117: 129-34. 136
  119. Marik PE. Leptin, obesity, and obstructive sleep apnea. Chest 2000; 118: 569-70. 137
  120. Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 1996; 334: 292-5. 138
  121. Snyder EM, Carr RD, Deacon CF et al. Overnight hypoxic expo- sure and glucagon-like peptide-1 and leptin levels in humans. Appl. Physiol. Nutr. Metab. 2008; 33: 929-35. 139
  122. Vgontzas AN, Papanicolaou DA, Bixler EO et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J. Clin. Endocrinol. Metab. 2000; 85: 1151-8. 140
  123. Phillips BG, Kato M, Narkiewicz K et al. Increases in leptin levels, sympathetic drive, and weight gain in obstructive sleep apnea. Am. J. Physiol. Heart Circ. Physiol. 2000; 279: H234-7. 141
  124. Ip MS, Lam KSL, Ho CM et al. Serum leptin and vascular risk factors in obstructive sleep apnea. Chest 2000; 118: 580-86. 142
  125. Tokuda F, Sando Y, Matsui H et al. Serum levels of adipocytok- ines, adiponectin and leptin in patients with obstructive sleep apnea syndrome. Intern Med 2008; 47: 1843-9. 143
  126. Ciftci TU, Kokturk O, Bukan N et al. Leptin and Ghrelin levels in patients with obstructive sleep apnea syndrome. Respiration 2005; 72: 395-401. 144
  127. Shimizu K, Chin K, Nakamura T et al. Plasma leptin levels and cardiac sympathetic function in patients with obstructive sleep apnoea-hypopnoea syndrome. Thorax 2002; 57: 429-34. 145
  128. Luo JD, Zhang GS, Chen MS. Leptin and cardiovascular diseases. Drug News Perspect. 2005; 18: 427-31. 146
  129. Parhami F, Tintut Y, Ballard A et al. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ. Res. 2001; 88: 954-60. 147
  130. Chin K, Shimizu K, Nakamura T et al. Changes in intra- abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. Circulation 1999; 100: 706-12. 148
  131. Harsch IA, Konturek PC, Koebnick C et al. Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment. Eur. Respir. J. 2003; 22: 251-7. 149
  132. Makowski L, Brittingham KC, Reynolds JM et al. The fatty acid- binding protein, aP2, coordinates macrophage cholesterol traf- ficking and inflammatory activity. Macrophage expression of aP2 impacts peroxisome. J. Biol. Chem. 2005; 280: 12888-95. 150
  133. Uysal KT, Scheja L, Wiesbrock SM et al. Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endo- crinology 2000; 141: 3388-96. 151
  134. Boord JB, Fazio S, Linton MF. Cytoplasmic fatty acid-binding proteins: emerging roles in metabolism and atherosclerosis. Curr. Opin. Lipidol. 2002; 13: 141-7. 152
  135. Makowski L, Boord JB, Maeda K et al. Lack of macrophage fatty- acid-binding protein aP2 protects mice deficient in apolipopro- tein E against atherosclerosis. Nat. Med. 2001; 7: 699-705. 154
  136. Tuncman G, Erbay E, Hom X et al. A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hyper- triglyceridemia, type 2 diabetes, and cardiovascular disease. Proc. Natl. Acad. Sci. U S A 2006; 103: 6970-75. 155
  137. Lam CL, Xu A, Lam KSL et al. Serum adipocyte-fatty acid binding protein level is elevated in severe OSA and correlates with insulin resistance. Eur. Respir. J. 2009; 33: 346- 51. 156
  138. Han Q, Yeung SC, Ip MS et al. Effects of intermittent hypoxia on A-/E-FABP expression in human aortic endothelial cells. Int. J. Cardiol. 2010; 145: 396-8.

Cited by

Sorted by citations

Authors
LAM, J. C. M., MAK, J. C. W., & IP, M. S. M.
Affiliations
Queen Mary Hospital (CN)
Venue
Respirology
Publisher
Wiley
Published
2012-01-24
Volume
17
Issue
2
Pages
223-236
ISSN
  • 1323-7799 (ISSN-L)
  • 1440-1843
DOI
10.1111/j.1440-1843.2011.02081.x
OpenAlex
W1480885089
Cited by
198
References
16
Citations by year
2026: 8 · 2025: 21 · 2024: 15 · 2023: 10 · 2022: 10 · 2021: 13 · 2020: 16 · 2019: 12 · 2018: 15 · 2017: 8 · 2016: 5 · 2015: 21 · 2014: 19 · 2013: 14 · 2012: 11
FWCI
1.50
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Respirology (publishedVersion)
  • PubMed (publishedVersion)
  • The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Obstructive Sleep Apnea Research
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroscience of respiration and sleep
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
Keywords
obstructive sleep apnea, obesity, metabolic syndrome, cardiometabolic dysfunction, intermittent hypoxia, sleep fragmentation, sympathetic activation, oxidative stress, inflammation, neurohumoral changes, cardiovascular morbidity, continuous positive airway pressure, lifestyle modification, diet
MeSH terms
Humans, Insulin Resistance, Obesity, Public Health, Risk Factors, Prevalence, Oxidative Stress, Developed Countries, Sleep Apnea, Obstructive, Metabolic Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review